Monitoring Mitochondrial Partial Oxygen Pressure During Cardiac Arrest and Extracorporeal Cardiopulmonary Resuscitation. An Experimental Pilot Study in a Pig Model

Loes Mandigers 1,*, Jan-Steffen Pooth 2, Mark A. Wefers Bettink 3, Corstiaan A. den Uil 1,4,5, Domagoj Damjanovic 2, Egbert G. Mik 3, Sam Brixius 2, Diederik Gommers 1, Georg Trummer 2 and Dinis dos Reis Miranda 1

1 Department of Intensive Care, Erasmus University Medical Center, Rotterdam, Netherlands, 2 Department of Cardiovascular Surgery, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 3 Department of Anaesthesiology, Erasmus University Medical Center, Rotterdam, Netherlands, 4 Department of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands, 5 Department of Intensive Care, Maasstad Hospital, Rotterdam, Netherlands

Introduction: Ischemia and reperfusion are crucial in determining the outcome after cardiac arrest and can be influenced by extracorporeal cardiopulmonary resuscitation (ECPR). The effect of ECPR on the availability and level of oxygen in mitochondria remains unknown. The aim of this study was to find out if skin mitochondrial partial oxygen pressure (mitoPO2) measurements in cardiac arrest and ECPR are feasible and to investigate its course.

Materials and Methods: We performed a feasibility test to determine if skin mitoPO2 measurements in a pig are possible. Next, we aimed to measure skin mitoPO2 in 10 experimental pigs. Measurements were performed using a cellular oxygen metabolism measurement monitor (COMET), at baseline, during cardiac arrest, and during ECPR using the controlled integrated resuscitation device (CIRD).

Results: The feasibility test showed continuous mitoPO2 values. Nine experimental pigs could be measured. Measurements in six experimental pigs succeeded. Our results showed a delay until the initial spike of mitoPO2 after ECPR initiation in all six experimental tests. In two experiments (33%) mitoPO2 remained present after the initial spike. A correlation of mitoPO2 with mean arterial pressure (MAP) and arterial partial oxygen pressure measured by CIRD (CIRD-PaO2) seemed not present. One of the experimental pigs survived.

Conclusions: This experimental pilot study shows that continuous measurements of skin mitoPO2 in pigs treated with ECPR are feasible. The delay in initial mitoPO2 and discrepancy of mitoPO2 and MAP in our small sample study could point to the possible value of additional measurements besides MAP to monitor the quality of tissue perfusion during cardiac arrest and ECPR.

Keywords: heart arrest, cardiac arrest, extracorporeal cardiopulmonary resuscitation, mitochondrial oxygen pressure, circulation monitoring
INTRODUCTION

In cardiac arrest, the duration of ischemia is an important determinant for survival and neurological outcome (1, 2). In order to shorten this ischemic period during cardiac arrest, extracorporeal cardiopulmonary resuscitation (ECPR) can be used to recover circulation and effective oxygen transport. The possible beneficial effect of ECPR on neurologically favorable survival has already been studied previously (3). However, the best treatment protocol of ECPR regarding ECPR settings is still unknown.

To determine if the recovery of circulation and oxygen delivery using ECPR are sufficient, we measured oxygen in the mitochondria, as final destination of oxygen. After all, mitochondria are important for generating energy, using oxygen, for cellular processes and maintaining life (4, 5). Protoporphyrine IX (PpIX) is an endogenously present porphyrin in the mitochondria, which can be enhanced by administering 5-aminolevulinic acid hydrochloride (ALA) crème (6). The subcellular distribution of PpIX in ALA stimulated cells has been studied using wide-field fluorescence microscopy (7). Previous research has shown the possibilities of measuring partial oxygen pressure (PO2) in the mitochondria by PpIX using its oxygen-dependent delayed fluorescence (7–10). To confirm that this delayed fluorescence truly measures inside the mitochondria, a previous study compared photobleaching (a contrast enhancement technique for PpIX) to MitoTracker Green (a method to identify mitochondria). This comparison showed a high degree of co-localization (7). This confirmed that, for a time window of several hours after ALA administration, PpIX measurements with delayed fluorescence corresponds to a mitochondrial localization (7). This method of measuring mitochondrial PO2 (mitoPO2) has also been validated to perform well in the skin (11). In addition, the possibility to perform continuous mitoPO2 measurements is shown in adults by Ubbink et al. (10) and in newborns by Costerus et al. (12).

The primary aim of this study is to find out if continuous measurements of skin mitoPO2 in a pig are feasible and what the course of this mitoPO2 is during cardiac arrest and ECPR. The secondary aims are to investigate if there is a correlation between the course of mitoPO2 and mean arterial pressure (MAP) and to identify the correlation between the course of mitoPO2 and favorable neurological survival.

METHODS

Between November 2017 and September 2020, 11 male and female German landrace pigs (weight: 50.0–82.0 kg) were eligible for skin mitoPO2 measurements. Continuous skin mitoPO2 measurements in pigs with experimental settings of cardiac arrest treated with ECPR have not been performed before. In order to determine if these measurements are possible to perform and feasible in our test set up we first performed a feasibility test in one pig. This test showed that continuous measurements in this set up was possible. Therefore, we selected 10 pigs to perform continuous skin mitoPO2 measurements as experimental test group. Of these 10 experimental tests, one could not be performed due to technical failure before the start of the test.

All animals received humane care and were treated in compliance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (13). The experiments were performed in accordance with the rules and regulations of the German animal protection law and the animal care guidelines of the European Community. The experiments were performed in the University of Freiburg, a highly experienced animal lab performing many ECPR procedures in pigs, and approved by the committee for ethics of the University Hospital Freiburg, Freiburg, Germany (no.G-15/148).

Preparation of Tests

After premedication (20 mg/kg ketamine and 0.5 mg/kg midazolam) an intravenous (IV) access was placed, the pigs were sedated and paralyzed (3–4 mg/kg propofol and 0.2 mg/kg vecuronium), intubated, and mechanically ventilated. Continuous intravenous anesthesia consisted of the administration of 10–15 mg/kg/h propofol, 1–5 µg/kg/h fentanyl and 0.2–0.4 mg/kg/h vecuronium. In the pre-arrest period the core temperature we aimed for was 36–38°C. This temperature was measured by a nasal temperature sensor and in case of a low body temperature the pig was heated using a warming blanket.

In order to perform mitoPO2 measurements, a part of the skin (~1 cm2) was prepared. First, hair was removed by shaving, the skin was roughened, and then the skin was cleaned using sodium chloride (NaCl 0.9%) and ethanol (70%). The 20% ALA crème was prepared by mixing 400 mg ALA (Fagron, Barsbüttel, Germany) with 2 g Lanettecrème 1 FNA (Teva Nederland BV, Haarlem NL) (6). To avoid photobleaching of PpIX by light, the applied ALA crème was directly covered by a plaster and by aluminum foil. The crème was placed 3 h before the first measurement and during this waiting time it was continuously protected to light (7, 11). Because of the use of a mechanical cardiopulmonary resuscitation (CPR) device and cannulation in the right groin and neck, we measured the mitoPO2 in the left axilla/neck region. Five minutes before induction of arrest, the effect of the ALA crème was tested by compression of the sensor on the skin (8, 10). When the measurements were finished, the skin was again covered to protect from light in order to protect it from burn lesions.

Abbreviations: ALA, 5-Aminolevulinic Acid Hydrochloride; ALS, Advanced Life Support; BLS, Basic Life Support; CARL, Controlled Automated Reperfusion of the Whole Body; CIDR, Controlled Integrated Resuscitation Device; CIDR-PaO2, Partial oxygen pressure measured by Controlled Integrated Resuscitation Device; CPR, Cardiopulmonary Resuscitation; COMET, Cellular Oxygen Metabolism Monitor; ECPR, Extracorporeal Cardiopulmonary Resuscitation; MAP, Mean Arterial Pressure; MitoPO2, Mitochondrial partial oxygen pressure; NaCl, Sodium Chloride; NDS, Neurologic Deficit Score; PO2, Partial Oxygen Pressure; PpIX, Protoporphyrine IX; ROSC, Return Of Spontaneous Circulation; VA-ECMO, Venoarterial-Extracorporeal Membrane Oxygenation; VF, Ventricular Fibrillation.
Test Procedure
The protocols and set up of the feasibility test and the experimental tests were slightly different, we will describe the test procedures separately.

Feasibility Test
Ventricular fibrillation (VF) was induced by electrical stimulation via a Swan-Ganz catheter (Edwards Lifesciences Corp., Irvine, CA, USA). During 20 min of cardiac arrest, venous and arterial access was surgically generated via the right external jugular vein (23 Fr cannula) and the right common femoral artery (17 Fr cannula), respectively. In the period of cardiac arrest, mechanical ventilation was stopped and no life support was applied. After 20 min of cardiac arrest, ECPR was initiated with blood flow varying from 5.9 to 7.6 L/min. External defibrillation was performed in case of persisting VF. ECPR was weaned and stopped 60 min after initiation. If the animal could be weaned from ECPR, it was subsequently weaned from the ventilator and transferred to the animal facility after extubation. The pig was examined daily and neurological outcome was scored using a modified species-specific neurological deficit score (NDS) (14). This NDS ranges from 0 (normal) to 500 (brain death) and a favorable outcome was defined as NDS below 50 (14, 15). Euthanasia was performed in tabula in case the pig could not be weaned off extracorporeal circulation or invasive ventilation, in case the pig was expected to have inhumane suffering or prolonged death (an NDS of >200 at 24 h or an NDS of >120 at 48 h), and otherwise after 7 days (15).

Experimental Tests
In the nine experimental tests, the ECPR implantation and induction of VF was the same as described in the feasibility test, except the timing of ECPR cannulation. In the experimental tests, this was already performed in the pre-arrest period. Next, after 5 min of VF, basic life support (BLS) was started with cardiopulmonary resuscitation (CPR) using a mechanical compression device (Corps CPR, GS Elektromedizinische Geräte G. Tempel GmbH, Kaufering, Germany) for 8 min. The next 22 min consisted of advanced life support (ALS), with additional administration of epinephrine every 4 min. After 35 min of cardiac arrest and CPR, ECPR was initiated with blood flow varying from 5.5 to 7.9 L/min and a 20 ml bolus of 7.45% potassium was applied for rhythm conversion. During ECPR in case of persisting VF, the heart was electrically defibrillated. If the VF sustained after three defibrillations, amiodarone and lidocaine were administered. If needed, continuous norepinephrine was administered with an aimed MAP of 60–80 mmHg. For these 10 experiments the controlled automated reperfusion of the whole body (CARL) protocol with the controlled integrated resuscitation device (CIRD, 1.0 Resuscitex GmbH, Freiburg/Germany) was used (15). ECPR was weaned around 120 min after initiation. This weaning consisted of slowly reducing the flow within 15–20 min until 1.5 L/min. If the pig displayed signs of sufficient circulation (i.e., arterial amplitude above 20 mmHg, MAP above 60 mmHg, and stable lactate measurements) ECPR was discontinued and surgically removed. All post ECPR care and neurologic outcome scoring was comparable to the feasibility test as described above.

MitoPO₂ Measurements
The background of PpIX delayed fluorescence measurements is described in detail elsewhere (7). In short, PpIX is the final precursor of heme and is synthesized inside the mitochondria (7). When ALA crème is applied to the skin it enhances the endogenously present PpIX. The PpIX accumulates inside the mitochondria and possesses a triplet state, which reacts strongly with oxygen and therefore it can be used as an intramitochondrial oxygen sensor (7). For this experiment we used the previously described cellular oxygen metabolism monitor (COMET, Photonics Healthcare B.V., Utrecht, The Netherlands) to measure mitoPO₂ (10). The effect of the ALA crème was tested with an oxygen-consumption measurement performed by applying pressure on the skin sensor. This pressure causes an occlusion of microcirculatory blood flow and therefore oxygen delivery to the mitochondria is stopped, resulting in a decrease of mitoPO₂ (8, 10). A decrease of mitoPO₂ to ≤5 mmHg and a return to baseline values after release of the pressure on the skin sensor was defined as successful oxygen-consumption measurement. This measurement was performed at least two times before induction of cardiac arrest. During cardiac arrest and during ECPR mitoPO₂ was measured every minute and, on indication, more often with a maximum frequency of every second for 60 s.

Other Measurements
Arterial PO₂ was measured via online blood gas sampling by the CIRD (CIRD-PaO₂). Systolic, diastolic, and mean arterial pressure were measured invasively via a carotid arterial cannula.
For the feasibility test we will plot the mitoPO₂ and CIRD-PaO₂ in a graph. All outliers of >200 mmHg will be set at 200 mmHg. The mitoPO₂ (in mmHg), CIRD-PaO₂ (in mmHg), and MAP (in mmHg) of the experimental tests will be plotted in graphs from baseline until discontinuation of ECPR flow, which will approximately be at 2.5–3.0 h after initiation of ECPR. Due to the small number of cases, the courses of these measured values cannot be compared using statistical testing. Therefore, the comparing of the graphs will be done by careful visual inspection.

### RESULTS

#### Feasibility Test

The feasibility test we performed, was to find out if skin mitoPO₂ measurements in a pig during cardiac arrest and ECPR were possible. As shown in Figure 1, mitoPO₂ of this case dropped after initiation of VF. When ECPR was initiated (after 20 min of VF), an initial spike in mitoPO₂ followed by a slow upslope was seen. After the initial spike, the level of mitoPO₂ remained high. This pig survived after ECPR weaning with a NDS at day 1 of 100, at day 2 a NDS of 60, and the following days a NDS of 0. Seven days after the experiment, it was euthanized according to the protocol.

#### Experimental Tests

Of the nine experimental tests we performed, four had to be excluded. A detailed description of reasons for exclusion is found in Supplementary Appendix A (10.6084/m9.figshare.13591211). In short, in one experimental test the skin with ALA was exposed to too much light. In two other experimental cases we failed to perform the measurements continuously during the tests. The last experimental case could not be performed due to complication during preparation. Two of these experimental pigs were male and two female.

We included six (50.0–70.5 kg) pigs in this experimental test group. The characteristics of the measurements of these pigs are reported in Table 1. Figures 2–4 show the course of mitoPO₂, CIRD-PaO₂, and MAP of the six experimental tests in separate graphs, from baseline (just before start of the cardiac arrest) until discontinuation of ECPR flow. In all pigs, directly after initiation of VF, the mitoPO₂ decreased rapidly. As shown in Table 2, the median time from initiation of VF until a mitoPO₂ of ≤5 mmHg was 29 s (interquartile range, IQR 23–60). The median time from initiation of ECPR until first rise in mitoPO₂ above 5 mmHg was 1,066 s (i.e., 17 min and 46 s, IQR 900–1,139 s).

In four of the six experimental tests (case 1, 2, 5, and 6), after initiation of ECPR the initial spike of mitoPO₂ did not result in persisting high mitoPO₂ values. In the other two experimental tests (case 3 and 4), after initiation of ECPR the initial spike of mitoPO₂ was followed by a continuous level of mitoPO₂ which approached baseline levels. There was no correlation between mitoPO₂, CIRD-PaO₂, and MAP in the tests without persisting mitoPO₂ values. In the two patients with continuous higher levels of mitoPO₂, comparing the correlation of mitoPO₂, CIRD-PaO₂, and MAP is complex. With careful visual inspection, the difference between the three values is smaller and seems somewhat related, especially in case 4. Case 3 could not be successfully weaned from ECPR due to technical problems. Case 4 survived after ECPR weaning. The NDS of this pig was 130 at day 1 and 2 and it was euthanized at day 2 due to humane reasons. All other cases could not be successfully weaned from the ECPR and died at termination of the experiment.

#### DISCUSSION

In this study we showed that skin mitoPO₂ measurements in a pig during cardiac arrest and ECPR are feasible. In all six experimental tests we found a rapid decrease of mitoPO₂ after initiation of VF and a remarkably delayed increase in the initial measured mitoPO₂ after reperfusion via ECPR. In four of the six cases no continuously high mitoPO₂ values were present. However, in two of the cases mitoPO₂ remained near baseline levels after the initial spike. The course of mitoPO₂ in these two cases seemed correlated with CIRD-PaO₂ and MAP. One of these pigs survived, but with an unfavorable neurological outcome until 2 days after the experiment.

The rapid decrease of mitoPO₂ after initiation of VF was expected to be found, because of the immediate stop of oxygen delivery and uptake due to whole body ischemia. Harms et al. (8) showed a rapid decrease of mitoPO₂ as soon as oxygen delivery to the skin is stopped by performing local pressure to the skin sensor, which occludes the microvessels, in a rat experiment. Ubbink et al. (10) repeated this test in humans and they also found a rapid decrease in mitoPO₂ when applying local pressure. After initiation of VF in our tests, systemic blood flow stops and
therefore there will be a rapid decrease in oxygen delivery. This disappearance of blood flow and oxygen delivery acts the same as the oxygen consumption tests performing pressure to occlude the microvessels. This demonstrates the close relationship of tissue perfusion and tissue oxygenation.

The delay of increase in mitoPO\textsubscript{2} after initiation of ECPR we found is most probably due to adrenaline administered during ALS according to the resuscitation guidelines. The possible effects of medication on mitoPO\textsubscript{2} has been shown before. Ubbink et al. (10) showed, as an incidental finding, that the initial vasoconstriction caused by clonidine decreased the skin mitoPO\textsubscript{2} values. There was no effect on capillary venous oxygen saturation, however the effect on mitoPO\textsubscript{2} and flow remained present for around 15 min (10). Adrenaline stimulates the $\alpha$1-receptors, among others, which causes vasoconstriction and centralization of blood flow (16). The effect of adrenaline on mitoPO\textsubscript{2} values has not been shown before. However, Fries et al. (17) showed that administration of adrenaline caused a decrease in capillary blood flow which persisted after the achievement of return of spontaneous circulation (ROSC). Therefore, administration of adrenaline might explain the delay of increase in skin mitoPO\textsubscript{2} values.

Another explanation for the delay of increase in mitoPO\textsubscript{2} after initiation of ECPR could be centralization, where the skin as an end organ will be the last organ to regain flow. After initiation of ECPR, the macrocirculation (MAP and blood flow) is restored immediately. However, the exact timing of restoration of the microcirculation in different tissues is unknown. In cardiac arrest, arterial blood flow decreases to zero and during CPR it will remain lower than normal (18). Therefore the
reduced stimulation of the arterial baroreceptors will activate the sympathetic system (19). This sympathetic system will centralize the blood flow and causes vasoconstriction to preserve heart and brain function (19). A hypothesis could be that when ECPR is initiated this vasoconstriction is present and only when the other vital organs are perfused, the perfusion of the skin will recover.

In four of the six experimental tests, the delay of increase in mitoPO2 despite systemic reperfusion suggests irreversible damage to tissue perfusion, tissue oxygenation, or oxygen transport to the mitochondria. In these four tests, after the initial spike of high mitoPO2 following ECPR initiation, no continuously high mitoPO2 values were measured until the end of the experiment. In the two tests with recovery of the skin mitoPO2 values, recovery of the tissue perfusion, tissue oxygenation, and oxygen transport to the mitochondria takes place. When high mitoPO2 values were measured after the initial spike, the values remained high. The inadequacy of tissue oxygenation and long ischemic period could eventually lead to a microcirculatory shut down. A global shut down in cases of ischemia was already reported before (20). After an ischemic episode, the microcirculation respiration can recover to a certain extent, depending on the duration of ischemia and level of reperfusion (20). Ruggieri et al. (21) stated that, after severe ischemia some muscle cells in the heart can be irreversibly damaged and demarcation will occur, while the incompletely effected tissue can recover partly. The difference in mitoPO2 course in the six experimental tests we performed could be explained by irreversible vs. incomplete affected tissue. We hypothesize that the quicker mitoPO2 rises could be explained by less ischaemic cellular damage which could cause sooner re-activation of the mitochondrial function and therefore less overall ischaemic/reperfusion damage.

MitoPO2 can be interpreted as determinant of the microcirculatory function. In order to regain oxygen levels into the mitochondria after cardiac arrest, tissue perfusion and tissue oxygenation have to be present. This tissue perfusion and oxygenation are largely influenced by an intact microcirculation. In case mitoPO2 is detected, it can be expected that microcirculation has at least partly been recovered. Bodmer et al. (22) performed a study measuring the microcirculation and mitoPO2 in the liver simultaneously. They found only a small difference of PO2 in the microcirculation and mitoPO2. Mik et al. (9) recently stated that average mitoPO2 appears to be close to microvascular PO2. MitoPO2 measured by PpIX delayed fluorescence provides an estimation of microvascular PO2 and therefore an it can be interpreted as determinant of the microcirculatory function.

The added value of monitoring microcirculatory function could be relevant in ECPR procedures, as the correlation between the mitoPO2 and MAP is not consistently present in this study. In contrast to the abovementioned delay in recovery of tissue oxygenation due to an impaired microcirculatory function, the macrocirculation (MAP and blood flow) was restored immediately upon initiation of ECPR. This discrepancy between mitoPO2, as a determinant of microcirculatory function, and MAP, as a determinant of macrocirculation, shows the importance of monitoring this microcirculatory function. Yu et al. (23) compared the microcirculation and macrocirculation and showed an inconsistent relation of microcirculation

---

**TABLE 2 | Summary of characteristics.**

| Time: initiation of VF until first low mitoPO2 (≤5 mmHg) | 29 (23–60) in seconds |
| Time: initiation ECPR until mitoPO2 > 5 mmHg | 1,066 (900–1,139) in seconds |
| Correlation of mitoPO2 and CIRD-PaO2 | 2/6 cases (66.7%) |
| ECPR survival | 1/6 cases (16.7%) |

The continuous variables are presented as medians and interquartile ranges, the categorical variables are presented as number and percentage.

VF, ventricular fibrillation; mitoPO2, mitochondrial partial oxygen pressure; BLS, basic life support; ALS, advanced life support; ECPR, extracorporeal cardiopulmonary resuscitation; CIRD-PaO2, partial oxygen pressure measured by controlled integrated resuscitation device.
(i.e., brain and brachioradial muscle) and macrocirculation (i.e., MAP) in pigs with cardiac arrest (23). Fritz et al. (24) performed ECPR in pigs, they found no differences in microcirculatory flow index at initiation and after 6 h of ECPR comparing the group treated with standard MAP to the group treated with high MAP. However, they did not directly investigate the relation between continuous microcirculatory function and MAP. In addition, two other studies compared microcirculation and macrocirculation in patients with cardiogenic shock treated with veno-arterial ECMO (VA-ECMO) (25, 26). Yeh et al. (26) showed no differences in early MAP for survivors and non-survivors, while early microcirculation was higher in survivors than in non-survivors. Chommeloux et al. (25) showed in successfully weaned patients despite normal MAP, normalization of microcirculatory values took 48 h after initiation of VA-ECMO. In order to apply personalized medicine and therefore a possible increase in the accuracy of treatment, monitoring of microcirculatory function should be the added to monitoring of macrocirculation.

In addition, the survival chance in pigs with continuously high mitoPO2 is probably higher than in pigs without continuously high mitoPO2. One of the two cases with continuously high mitoPO2 survived this experiment. The other one died because of technical failure. In the experiments with pigs without continuously high mitoPO2, none of them survived. No previous studies aimed on the course of mitoPO2 measurements in ECPR in relation to survival outcome. However, Fries et al. (17) found less increase in microcirculation (i.e., capillary flow) in animals that failed resuscitation in a model with chest compressions. Furthermore, within 5 min of ROSC, microcirculation returned only within 20% of baseline values (17). This could point to the possible additional value of monitoring microcirculatory function during CPR, during ECPR, and after ROSC.

This study has several limitations. First, our sample size is small and of the experimental measurements only one pig survived. Therefore, we could not perform statistical tests to identify the correlation of the course of mitoPO2 and survival or favorable neurological survival. Possible hypotheses for the low successful weaning numbers in this studies are described in the Supplementary Appendix B. Second, because of the preparation time of the ALA crème, mitoPO2 measurements cannot be used during cardiac arrest and within the first hours after ECPR initiation in humans. In order to test our hypotheses and get more understanding of the pathophysiology, future experimental research should aim at the correlation of the course of mitoPO2 and survival. Also, the course of mitoPO2 comparing conventional CPR with ROSC and ECPR cases could extend the existing knowledge. Another topic which needs to be investigated in future research is if, in humans treated with ECPR, monitoring the microcirculatory function is a more accurate target than monitoring the macrocirculation in order to apply a more individually based treatment. If a method is found to shorten the time needed for ALA-induced PpIX enhancement within cells (e.g., with intravenous administration), mitoPO2 measurements during ECPR could be also performed in humans.

**CONCLUSION**

This experimental pilot study shows that continuous measurements of skin mitoPO2 in pigs treated with ECPR are feasible. The delay in initial mitoPO2 and discrepancy of mitoPO2 and MAP in our small sample study could point to the possible value of additional measurements besides MAP to monitor the quality of tissue perfusion during cardiac arrest and ECPR.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

**ETHICS STATEMENT**

The animal study was reviewed and approved by Committee for Ethics of the University Hospital Freiburg, Freiburg, Germany (No. G-15/148).

**AUTHOR CONTRIBUTIONS**

LM participated in the study design, acquired, analyzed, interpreted the data, and drafted and revised the manuscript. J-SP helped acquiring, analyzing, and interpreting the data and was a contributor in revising the manuscript. MW and DD helped interpreting the data and were major contributors in revising the manuscript. CU participated in the study design, helped interpreting the data, and was a major contributor in revising the manuscript. EM and GT participated in the study design, helped interpreting the data, and drafted and revised the manuscript. J-LM participated in the study design, acquired, analyzed, and interpreted the data and were major contributors in revising the manuscript. SB helped acquiring, analyzing, and interpreting the data and was a major contributor in revising the manuscript. DR majorly contributed to the conception of the study, participated in the study design, helped interpreting the data, and was a major contributor in revising the manuscript. All authors read and approved the final manuscript.

**ACKNOWLEDGMENTS**

We want to thank Patricia Specht for preparing the test material for all of the tests.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.754852/full#supplementary-material
REFERENCES

1. Martinell L, Nielsen N, Herlitz J, Karlsson T, Horn J, Wise MP, et al. Early predictors of poor outcome after out-of-hospital cardiac arrest. Crit Care. (2017) 21:96. doi: 10.1186/s13054-017-1677-2

2. Adnet P, Triba MN, Borron SW, Lapostolle F, Hubert H, Guergniaud PY, et al. Cardiopulmonary resuscitation duration and survival in out-of-hospital cardiac arrest patients. Resuscitation. (2017) 111:74–81. doi: 10.1016/j.resuscitation.2016.11.024

3. Holmberg MJ, Geri G, Wiberg S, Guerguerian AM, Donnino MW, Nolan JP, et al. Extracorporeal cardiopulmonary resuscitation for cardiac arrest: a systematic review. Resuscitation. (2018) 131:91–100. doi: 10.1016/j.resuscitation.2018.07.029

4. Gvozdjáková A. Mitochondrial Medicine. Mitochondrial Medicine; Mitochondrial Metabolism, Diseases, Diagnosis and Therapy. Dordrecht: Springer Science + Business Media B.V. (2008) p. 1–17.

5. Skulachev VP. Mitochondrial physiology and pathology; concepts of programmed death of organelles, cells and organisms. Mol Aspects Med. (1999) 20:139–84. doi: 10.1016/S0098-2997(99)00008-4

6. Harms FA, de Boon WM, Balestra GM, Bodmer SI, Johannes T, Stolker RJ, et al. Oxygen-dependent delayed fluorescence measured in skin after topical application of 5-aminolevulinic acid. J Biophotonics. (2011) 4:731–9. doi: 10.1002/jbio.201100040

7. Mik EG, Stojan S, Sinaasappel M, Beek JF, Aten JA, van Leeuwen TG, et al. Mitochondrial PO2 measured by delayed fluorescence of endogenous protoporphyrin IX. Nat Methods. (2006) 3:939–45. doi: 10.1038/nmeth940

8. Harms FA, Voorbeijtelen WJ, Bodmer SI, Raat NJ, Mik EG. Cutaneous respirometry by dynamic measurement of mitochondrial oxygen tension for monitoring mitochondrial function in vivo. Mitochondrion. (2013) 13:507–14. doi: 10.1016/j.mito.2012.10.005

9. Mik EG, Balestra GM, Harms FA. Monitoring mitochondrial PO2: the next step. Curr Opin Crit Care. (2020) 26:289–95. doi: 10.1097/MCC.0000000000000719

10. Ubbink R, Bettink MAW, Janse R, Harms FA, Johannes T, Munker FM, et al. A monitor for Cellular Oxygen METabolism (COMET); monitoring tissue oxygenation at the mitochondrial level. J Clin Monit Comput. (2017) 31:1143–50. doi: 10.1007/s10877-016-9966-x

11. Harms FA, Bodmer SI, Raat NJ, Stolker RJ, Mik EG. Validation of the protoporphyrin IX-triplet state lifetime technique for mitochondrial oxygen measurements in the skin. Opt Lett. (2012) 37:2625–7. doi: 10.1364/OL.37.002625

12. Costerus SA, Bettink MW, Tibboel D, de Graaff JC, Mik EG. Mitochondrial oxygen monitoring during surgical repair of congenital diaphragmatic hernia or esophageal atresia: a feasibility study. Front Pediatr. (2020) 8:532. doi: 10.3389/fped.2020.00532

13. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, DC: National Academies Press. (2011)

14. Forbess JM, Ibla JC, Lidov HG, Cioffi MA, Hiramatsu T, Laussen P, et al. University of Wisconsin cerebroplegia in a piglet survival model of circulatory arrest. Ann Thorac Surg. (1995) 60:549–500. doi: 10.1016/0003-4975(95)00876-4

15. Taunyane IC, Benk C, Beyersdorf F, Foerster K, Cristina Schmitz H, Wittmann K, et al. Preserved brain morphology after controlled automated reperfusion of the whole body following normothermic circulatory arrest time of up to 20 minutes. Eur J Cardiothorac Surg. (2016) 50:1025–34. doi: 10.1093/eucts/ezw186

16. Gough CJR, Nolan JP. The role of adrenaline in cardiopulmonary resuscitation. Crit Care. (2018) 22:139. doi: 10.1186/s13054-018-2058-1

17. Fries M, Weil MH, Chang YT, Castillo C, Tang W. Microcirculation during cardiac arrest and resuscitation. Crit Care Med. (2006) 34:A545–7. doi: 10.1097/01.CCM.0000247717.81480.B2

18. McDonald JL. Systolic and mean arterial pressures during manual and mechanical CPR in humans. Ann Emerg Med. (1982) 11:292–5. doi: 10.1016/S0196-0644(82)80125-X

19. Dunser MW, Takala J, Brunauer A, Bakker J. Re-thinking resuscitation: leaving blood pressure cosmetics behind and moving forward to permissive hypotension and a tissue perfusion-based approach. Crit Care. (2013) 17:326. doi: 10.1186/cc12727

20. Chun K, Zhang J, Biewer J, Ferguson D, Clemens MG. Microcirculatory failure determines lethal hepatocyte injury in ischemic/reperfusion rat livers. Shock. (1994) 1:3–9. doi: 10.1097/00024382-199401000-00002

21. Ruggieri AJ, Levy RJ, Deutschman CS. Mitochondrial dysfunction and resuscitation in sepsis. Crit Care Clin. (2010) 26:567–75, x-xl. doi: 10.1016/j.ccc.2010.04.007

22. Bodmer SI, Balestra GM, Harms FA, Johannes T, Raat NJ, Stolker RJ, et al. Microvascular and mitochondrial PO2(2) simultaneously measured by oxygen-dependent delayed luminescence. J Biophotonics. (2012) 5:140–51. doi: 10.1002/jbio.201100082

23. Yu J, Ramadeen A, Tsui AK, Hu X, Zou L, Wilson DF, et al. Quantitative assessment of brain microvascular and tissue oxygenation during cardiac arrest and resuscitation in pigs. Anaesthesia. (2013) 68:723–35. doi: 10.1111/anae.12227

24. Fritz C, Kimmoun A, Vanhuysse F, Trifan BF, Orloski S, Falanga A, et al. High versus low blood-pressure target in experimental ischemic prolonged cardiac arrest treated with extra corporeal life support. Shock. (2017) 47:759–64. doi: 10.1097/SHK.0000000000000793

25. Chommelou J, Montero S, Farmache G, Brechot N, Hekimian G, Lebretton G, et al. Microcirculation evolution in patients on venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med. (2020) 48:e9–e17. doi: 10.1097/CCM.0000000000004072

26. Yeh YC, Lee CT, Wang CH, Tu YK, Lai CH, Wang YC, et al. Investigation of microcirculation in patients with venoarterial extracorporeal membrane oxygenation life support. Crit Care. (2018) 22:200. doi: 10.1186/s13054-018-2081-2

Conflict of Interest: DR declares having received speaking fees from Xenios GmbH and HillRom GmbH. EM is listed as inventor on patents related to mitochondrial oxygen measurements held by the Academic Medical Center Amsterdam and the Erasmus Medical Center Rotterdam, the Netherlands. EM is founder and shareholder of Photonics Healthcare, a company that holds exclusive licenses to these patents and that markets the COMET system. DG is a member of the medical advisory board of Xenios GmbH and received travel expenses and speaker fees from Xenios and Maquet GmbH. GT is shareholder of Resuscitec GmbH.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Mandigers, Pooth, Wefers Bettink, Uil, Damjanovic, Mikk, Brixius, Gommers, Trummer and dos Reis Miranda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.